Skip to main contentAI and Advanced
/
THEMISMED · NSEMarket ticker unavailable · configure an authorised index feed
TH
NSE · Equity shares · Major Drugs0.90 · 0.75%
Themis Medicare THEMISMED
NSE:INR 121
BSE:INR 110.2
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for THEMISMED
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 120.1
Day rangeINR 116 — INR 123.48
52-week rangeINR 64.95 — INR 148
Volume61,249
Market cap1,015.38
P/E508.23
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)342.24
Net Income (INR Cr)1.14
Rev Growth (5 Year %)8.21
EPS Growth (5 Year %)-50.11
P/E Ratio508.23
Book Value43.26
EPS0.17
Price/BV2.80Computed
Research path: Interpret Themis Medicare's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
THEMISMEDThemis Medicare1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 597.91 | 588.03 | 566.42 |
| Cash Equivalents | 4.61 | Not available | Not available |
| Other Liabilities Total | 1.94 | 1.86 | 0 |
| Long Term Debt | 21.86 | 16.22 | 24.69 |
| Common Stock Total | 9.21 | 9.2 | 9.2 |
| Other Current Assets Total | 30.21 | 13.53 | 15.36 |
| Total Assets | 597.91 | 588.03 | 566.42 |
| Current Portof LT Debt/Capital Leases | 78.23 | 21.94 | 21.66 |
| Cash | 4.54 | 6.56 | 9.92 |
| Total Equity | 398.58 | 402.6 | 377.67 |
| Long Term Investments | 110.05 | 95.95 | 89.82 |
| Retained Earnings(Accumulated Deficit) | 389.37 | 393.44 | 368.51 |
| Total Common Shares Outstanding | 9.21 | 9.2 | 9.2 |
| Tangible Book Valueper Share Common Eq | 43.26 | 43.71 | 40.97 |
| Total Liabilities | 199.32 | 185.43 | 188.75 |
| Total Debt | 100.09 | 82.99 | 95.79 |
| Short Term Investments | 6.41 | 0 | 0 |
| Cashand Short Term Investments | 15.56 | 6.56 | 9.93 |
| Total Receivables Net | 178.12 | 193.69 | 191.09 |
| Deferred Income Tax | 9.37 | 8.83 | 7.39 |
| Accounts Receivable-Trade Net | 178.12 | 177.1 | 178.11 |
| Property/Plant/Equipment Total-Net | 168.87 | 174.54 | 170.42 |
| Minority Interest | 0 | 0 | 0 |
| Total Current Liabilities | 166.16 | 156.12 | 154.58 |
| Total Inventory | 81.09 | 84.31 | 70.57 |
| Accounts Payable | 50.84 | 51.44 | 47.29 |
| Other Currentliabilities Total | 37.1 | 40.31 | 38.27 |
| Total Long Term Debt | 21.86 | 18.61 | 26.77 |
| Intangibles Net | 0.12 | 0.33 | 0.55 |
| Other Long Term Assets Total | 13.9 | Not available | Not available |
| Total Current Assets | 304.98 | 303.87 | 293.17 |
| Accumulated Depreciation Total | Not available | -78.23 | -69.17 |
| Other Equity Total | Not available | -0.05 | -0.05 |
| Prepaid Expenses | Not available | 5.76 | 6.22 |
| Property/Plant/Equipment Total-Gross | Not available | 250.26 | 236.98 |
| Notes Payable/Short Term Debt | Not available | 42.44 | 47.36 |
| Note Receivable-Long Term | Not available | 13.34 | 12.46 |
| Capital Lease Obligations | Not available | 2.39 | 2.08 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %2.8
Margins
Operating Margin 12m-3.15
Operating Margin 5y Avg11.22
Net Profit Margin 12m0.33
Net Profit Margin 5y10.88
Yield
Dividend Yield %0.45
Valuation
Price to Sale Ratio2.97
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk55.59
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Aurobindo Pharma | INR 1,533.95 | 88,425.24 | 25.09 | — |
| Neuland Laboratories | INR 18,400 | 23,672.85 | 64.28 | — |
| Pfizer | INR 4,593 | 20,966.13 | 27.53 | — |
| Unichem Laboratories | INR 535.75 | 3,771.99 | 54.27 | — |
| Jagsonpal Pharmaceuticals | INR 222 | 1,456.38 | 34.27 | — |
Shareholding
Ownership
- Promoter
- 67.11%
- FII
- 0.01%
- Other
- 32.88%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Corporate actions
Events
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results & issue of Warrants
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.0.5000 per share(50%)Final Dividend
- board MeetingsQuarterly Results
- board MeetingsAudited Results & Final Dividend
Rusaka Markets Community
Discussion and sentiment for Themis Medicare
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Themis Medicare Limited is a research-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. The Company specializes in manufacturing a range of products for application areas like pain management, critical care and anti-infectives. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more.
Company facts
- Industry
- Major Drugs
- Sector
- Major Drugs
- NSE Code
- THEMISMED
- BSE Code
- 530199
Questions
Stock FAQ
What is the symbol and ISIN of Themis Medicare?
Themis Medicare has the symbol THEMISMED and ISIN - INE083B01024.
What is the current price of Themis Medicare?
Themis Medicare is currently trading at INR 121.00.
What are the year high and year low of Themis Medicare?
Themis Medicare has a year high of INR 148.00 and a year low of INR 64.95.
What is the market capitalization of Themis Medicare?
Themis Medicare has a market capitalization of INR 1,015.38 crore.
What is the P/E ratio of Themis Medicare?
Themis Medicare has a P/E ratio of 508.23.
What is the dividend yield of Themis Medicare?
Themis Medicare has a dividend yield of 0.45%.
How is the financial performance of Themis Medicare based on revenue, net income, and EPS?
Themis Medicare has revenue of INR 342.24 crore, net income of INR 1.14 crore, and EPS of INR 0.21.
What is the book value of Themis Medicare?
Themis Medicare has a book value of INR 43.26.
What is the debt-to-equity ratio of Themis Medicare?
Themis Medicare has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Themis Medicare?
Themis Medicare has a price-to-book ratio of 2.80 and a price-to-sales ratio of 2.97.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.